Traders overwhelmingly favor an 80–90 flu hospitalization rate per 100,000 population for Week 11, 2026 (97.9% market-implied probability), reflecting CDC historical FluView data where late-winter peaks typically cluster around 8–9 per 100,000 during moderate seasons, scaled for market resolution. This positioning aligns with multiyear averages from 2010–2024, when H3N2 or B/Victoria dominance drove rates in this range amid standard vaccine effectiveness (40–60%). Current 2024–25 season trends show rising but sub-peak activity (under 5 per 100,000 as of early December), reinforcing expectations absent major shifts. Challenges include antigenic drift causing vaccine mismatch for 100+ spikes, or enhanced population immunity yielding <60 lows, per prior mild seasons like 2023–24.
Resumen experimental generado por IA con datos de Polymarket · ActualizadoFlu Hospitalization Rate Week 11, 2026?
Flu Hospitalization Rate Week 11, 2026?
80–90 97.8%
<60 1.3%
60–70 1.0%
70–80 1.0%
<60
1%
60–70
1%
70–80
1%
80–90
98%
90–100
1%
100+
1%
80–90 97.8%
<60 1.3%
60–70 1.0%
70–80 1.0%
<60
1%
60–70
1%
70–80
1%
80–90
98%
90–100
1%
100+
1%
If the recorded data falls exactly between two brackets, this market will resolve to the higher bracket.
The resolution source for this market will be CDC FluView / FluSurv-NET (see: https://www.cdc.gov/fluview/index.html). If the FluSurv-NET hospitalization rate for the specified week is not released by 11:59 PM ET on the tenth calendar day following the date of the prior FluView weekly report release, this market will resolve to the lowest bracket.
Note: Only the CDC FluSurv-NET cumulative hospitalization rate per 100,000 population for the specified week will qualify, regardless of estimates, projections, state-level reports, or other influenza surveillance metrics published by the CDC or other sources.
Mercado abierto: Mar 20, 2026, 2:29 PM ET
Resolver
0x69c47De9D...Resolver
0x69c47De9D...Traders overwhelmingly favor an 80–90 flu hospitalization rate per 100,000 population for Week 11, 2026 (97.9% market-implied probability), reflecting CDC historical FluView data where late-winter peaks typically cluster around 8–9 per 100,000 during moderate seasons, scaled for market resolution. This positioning aligns with multiyear averages from 2010–2024, when H3N2 or B/Victoria dominance drove rates in this range amid standard vaccine effectiveness (40–60%). Current 2024–25 season trends show rising but sub-peak activity (under 5 per 100,000 as of early December), reinforcing expectations absent major shifts. Challenges include antigenic drift causing vaccine mismatch for 100+ spikes, or enhanced population immunity yielding <60 lows, per prior mild seasons like 2023–24.
Resumen experimental generado por IA con datos de Polymarket · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes